Amgen Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
369.53 ^USD	+0.53%		-4.80%	+12.90%

Mar. 05	Arcutis Biotherapeutics, Inc. Announces Promotion of Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary	CI
Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI

Published on 02/03/2026 at 05:39 pm EST - Modified on 02/06/2026 at 05:50 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

My name is Julianne, and I will be your conference facilitator today for the Amgen Q4 2025 Earnings Conference Call. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Mar. 05	Arcutis Biotherapeutics, Inc. Announces Promotion of Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary	CI
Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 04	Amgen Keeps Quarterly Dividend at $2.52 a Share, Payable June 5 to Holders of Record May 15	MT
Mar. 04	Amgen announces 2026 second quarter dividend	RE
Mar. 04	Amgen Announces 2026 Second Quarter Dividend, Payable on June 5, 2026	CI
Mar. 04	NervGen Pharma Corp. Announces Executive Changes	CI
Mar. 03	Absci Corporation Announces Executive Changes	CI
Mar. 03	Kyowa Kirin stops development of skin condition treatment	RE
Mar. 03	Kyowa Kirin announces discontinuation of Rocatinlimab clinical trials	RE
Mar. 03	Kyowa Kirin Co., Ltd. Discontinues All Ongoing Clinical Trials for Rocatinlimab	CI
Mar. 02	Amgen Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 01:10 PM
Mar. 01	Fujian Haixi Pharmaceuticals Co., Ltd. Appoints Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, Effective March 1, 2026	CI
Feb. 27	Generate Biomedicines shares fall in weak Nasdaq debut for drug developer	RE
Feb. 27	Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut	RE
Feb. 23	Zura Bio Limited Announces Board Changes, Effective February 21, 2026	CI